You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClidinium
Accession NumberDB00771  (APRD00737)
TypeSmall Molecule
GroupsApproved
DescriptionClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Structure
Thumb
Synonyms
3-(2-Hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
3-Hydroxy-1-methylquinuclidinium benzilate ester
Bromure de Clidinium
Bromuro de clidinio
Clidinii Bromidum
CLIDINIUM
Clidinium bromid
N-Methyl quinuclidinyl benzilate
External Identifiers
  • Ro 2-3773
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DolibraxRoche
PorsuconYing Yuan
QuarzanRoche
SedaspaHua Shin
Brand mixtures
NameLabellerIngredients
ChloraxAa Pharma Inc
Chlordiazepoxide Hydrochloride and Clidinium BromideAcella Pharmaceuticals, LLC
Chlordiazepoxide Hydrochloride/clidinium BromideAv Kare, Inc.
Corium CapIcn Canada Ltd.
LibraxValeant Pharmaceuticals International
Nu-chlorax Capsules USPNu Pharm Inc
Pro ChloraxPro Doc Limitee
Salts
Name/CASStructureProperties
Clidinium Bromide
ThumbNot applicableDBSALT000958
Categories
UNIIBO76JF850N
CAS number7020-55-5
WeightAverage: 352.4467
Monoisotopic: 352.191268703
Chemical FormulaC22H26NO3
InChI KeyInChIKey=HOOSGZJRQIVJSZ-NNBUQUNQSA-N
InChI
InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+
IUPAC Name
(1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium
SMILES
C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylacetate
  • Quinuclidine
  • Piperidine
  • Tertiary alcohol
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
PharmacodynamicsClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
Mechanism of actionInhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9243
Blood Brain Barrier+0.9142
Caco-2 permeable+0.671
P-glycoprotein substrateSubstrate0.8526
P-glycoprotein inhibitor INon-inhibitor0.7661
P-glycoprotein inhibitor IINon-inhibitor0.9576
Renal organic cation transporterInhibitor0.6314
CYP450 2C9 substrateNon-substrate0.7781
CYP450 2D6 substrateNon-substrate0.6956
CYP450 3A4 substrateSubstrate0.6095
CYP450 1A2 substrateNon-inhibitor0.9528
CYP450 2C9 inhibitorNon-inhibitor0.9459
CYP450 2D6 inhibitorInhibitor0.6154
CYP450 2C19 inhibitorNon-inhibitor0.9577
CYP450 3A4 inhibitorNon-inhibitor0.9504
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9889
Ames testNon AMES toxic0.8557
CarcinogenicityNon-carcinogens0.933
BiodegradationReady biodegradable0.7763
Rat acute toxicity2.4948 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8162
hERG inhibition (predictor II)Non-inhibitor0.6539
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Prices
Unit descriptionCostUnit
Quarzan 5 mg capsule0.3USD capsule
Quarzan 2.5 mg capsule0.23USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point240-241 °CSternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche, Inc.
Predicted Properties
PropertyValueSource
Water Solubility0.000377 mg/mLALOGPS
logP-0.5ALOGPS
logP-1.1ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity112.14 m3·mol-1ChemAxon
Polarizability38.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Sternbach, L.H.; US. Patent 2,648,667; August 11,1953; assigned to Hoffmann-LaRoche,
Inc.

General ReferencesNot Available
External Links
ATC CodesA03CA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Clidinium.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Clidinium.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Clidinium.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Clidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clidinium.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Clidinium.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Clidinium.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clidinium.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Clidinium.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clidinium.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Clidinium.
AmoxapineThe risk or severity of adverse effects can be increased when Clidinium is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Clidinium.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Clidinium.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Clidinium.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Clidinium.
AzelastineClidinium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clidinium.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Clidinium.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Clidinium.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clidinium.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Clidinium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Clidinium is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
BrimonidineThe risk or severity of adverse effects can be increased when Clidinium is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Clidinium.
BrompheniramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Clidinium.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Clidinium.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Clidinium.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Clidinium.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Clidinium.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Clidinium.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Clidinium.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Clidinium.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Clidinium.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clidinium.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clidinium.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Clidinium.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Clidinium.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clidinium.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Clidinium.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Clidinium.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clidinium.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Clidinium.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clidinium.
ChlorphenamineThe risk or severity of adverse effects can be increased when Clidinium is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clidinium.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clidinium.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clidinium.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clidinium.
CitalopramThe risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Clidinium.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Clidinium.
ClomipramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clidinium is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clidinium.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Clidinium.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Clidinium.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Clidinium.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Clidinium.
CyclizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Clidinium.
DantroleneThe risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Clidinium.
DapoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Clidinium.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Clidinium.
DesipramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Clidinium.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clidinium.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Clidinium.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Clidinium.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Clidinium.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Clidinium.
DifenoxinThe risk or severity of adverse effects can be increased when Clidinium is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Clidinium.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Clidinium.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Clidinium.
DimenhydrinateThe risk or severity of adverse effects can be increased when Clidinium is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Clidinium.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Clidinium.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Clidinium.
DoxepinThe risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
DoxylamineThe risk or severity of adverse effects can be increased when Clidinium is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Clidinium.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Clidinium.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Clidinium.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Clidinium.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Clidinium.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Clidinium.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clidinium.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Clidinium.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Clidinium.
EscitalopramThe risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Clidinium.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clidinium.
EthanolClidinium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Clidinium.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clidinium.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Clidinium.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Clidinium.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Clidinium.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clidinium.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Clidinium.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Clidinium.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Clidinium.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Clidinium.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clidinium.
EtoperidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Clidinium.
EzogabineThe risk or severity of adverse effects can be increased when Clidinium is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Clidinium is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Clidinium.
FenfluramineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Clidinium.
FexofenadineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Clidinium.
FlunarizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Clidinium.
FluoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Clidinium.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clidinium.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Clidinium.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Clidinium.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Clidinium.
FluvoxamineThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Clidinium is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clidinium.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Clidinium.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Clidinium is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Clidinium.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Clidinium.
GuanfacineThe risk or severity of adverse effects can be increased when Clidinium is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Clidinium.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Clidinium.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Clidinium.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clidinium.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clidinium.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Clidinium.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
HydroxyzineThe risk or severity of adverse effects can be increased when Clidinium is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clidinium.
IndalpineThe risk or severity of adverse effects can be increased when Clidinium is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Clidinium.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clidinium.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clidinium.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Clidinium.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Clidinium.
LevetiracetamThe risk or severity of adverse effects can be increased when Clidinium is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Clidinium.
LevocabastineThe risk or severity of adverse effects can be increased when Clidinium is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Clidinium is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Clidinium is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Clidinium.
LevomilnacipranThe risk or severity of adverse effects can be increased when Clidinium is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Clidinium.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Clidinium.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Clidinium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Clidinium.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Clidinium.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Clidinium.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clidinium.
Lu AA21004The risk or severity of adverse effects can be increased when Clidinium is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clidinium is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Clidinium is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Clidinium.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Clidinium.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Clidinium.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Clidinium.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clidinium.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Clidinium.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Clidinium.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Clidinium.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clidinium.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Clidinium.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Clidinium.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Clidinium.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Clidinium.
MethsuximideThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Clidinium.
MetyrosineClidinium may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.
MilnacipranThe risk or severity of adverse effects can be increased when Clidinium is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
MirtazapineClidinium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clidinium.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Clidinium.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Clidinium.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
NabiloneThe risk or severity of adverse effects can be increased when Clidinium is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Clidinium.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Clidinium.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Clidinium.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Clidinium.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Clidinium.
OlanzapineThe risk or severity of adverse effects can be increased when Clidinium is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clidinium.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Clidinium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Clidinium.
OrphenadrineClidinium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Clidinium.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Clidinium.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clidinium.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Clidinium.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Clidinium.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Clidinium.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Clidinium.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Clidinium.
ParaldehydeClidinium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Clidinium.
ParoxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Clidinium.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clidinium.
PerampanelThe risk or severity of adverse effects can be increased when Clidinium is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Clidinium.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Clidinium.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Clidinium.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Clidinium.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Clidinium.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Clidinium.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Clidinium.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clidinium.
PipotiazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Clidinium is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.
PramipexoleClidinium may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clidinium.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Clidinium.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Clidinium.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Clidinium.
PrimidoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Clidinium.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.
PromethazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Clidinium.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Clidinium.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Clidinium.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Clidinium.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clidinium.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.
RamelteonThe risk or severity of adverse effects can be increased when Clidinium is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clidinium.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Clidinium.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clidinium.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Clidinium.
RopiniroleClidinium may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium.
RotigotineClidinium may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Clidinium.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Clidinium.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Clidinium.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clidinium.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Clidinium.
SertralineThe risk or severity of adverse effects can be increased when Clidinium is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clidinium.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Clidinium.
StiripentolThe risk or severity of adverse effects can be increased when Clidinium is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Clidinium.
SuvorexantThe risk or severity of adverse effects can be increased when Clidinium is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Clidinium is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Clidinium is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Clidinium.
TetrabenazineThe risk or severity of adverse effects can be increased when Clidinium is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Clidinium.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Clidinium.
ThalidomideClidinium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Clidinium.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clidinium.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Clidinium.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Clidinium.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Clidinium.
TiagabineThe risk or severity of adverse effects can be increased when Clidinium is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Clidinium.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clidinium.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Clidinium.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Clidinium.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Clidinium.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Clidinium.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clidinium.
TrazodoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Clidinium.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Clidinium.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clidinium.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Clidinium.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Clidinium.
VigabatrinThe risk or severity of adverse effects can be increased when Clidinium is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Clidinium is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Clidinium is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Clidinium.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clidinium.
ZiconotideThe risk or severity of adverse effects can be increased when Clidinium is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Clidinium is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Clidinium.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Clidinium.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Clidinium.
ZonisamideThe risk or severity of adverse effects can be increased when Clidinium is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Clidinium.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Clidinium.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clidinium.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23